Literature DB >> 15833850

Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases.

Yi Tang1, Marian T Nakada, Prabakaran Kesavan, Francis McCabe, Hillary Millar, Patricia Rafferty, Peter Bugelski, Li Yan.   

Abstract

Matrix metalloproteinases (MMPs) are endopeptidases that play pivotal roles in promoting tumor disease progression, including tumor angiogenesis. In many solid tumors, MMP expression could be attributed to tumor stromal cells and is partially regulated by tumor-stroma interactions via tumor cell-associated extracellular matrix metalloproteinase inducer (EMMPRIN). The role of EMMPRIN during tumor angiogenesis and growth was explored by modulating EMMPRIN expression and activity using recombinant DNA engineering and neutralizing antibodies. In human breast cancer cells, changes in EMMPRIN expression influenced vascular endothelial growth factor (VEGF) production at both RNA and protein levels. In coculture of tumor cells and fibroblasts mimicking tumor-stroma interactions, VEGF expression was induced in an EMMPRIN- and MMP-dependent fashion, and was further enhanced by overexpressing EMMPRIN. Conversely, VEGF expression was inhibited by suppressing EMMPRIN expression in tumor cells, by neutralizing EMMPRIN activity, or by inhibiting MMPs. In vivo, EMMPRIN overexpression stimulated tumor angiogenesis and growth; both were significantly inhibited by antisense suppression of EMMPRIN. Expression of both human and mouse VEGF and MMP, derived from tumor and host cells, respectively, was regulated by EMMPRIN. These results suggest a novel tumor angiogenesis mechanism in which tumor-associated EMMPRIN functionally mediates tumor-stroma interactions and directly contributes to tumor angiogenesis and growth by stimulating VEGF and MMP expression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15833850     DOI: 10.1158/0008-5472.CAN-04-3605

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  126 in total

1.  CD147 overexpression is a prognostic factor and a potential therapeutic target in bladder cancer.

Authors:  Yi-Jun Xue; Qiang Lu; Zhi-Xi Sun
Journal:  Med Oncol       Date:  2010-05-28       Impact factor: 3.064

2.  Basigin/CD147 promotes renal fibrosis after unilateral ureteral obstruction.

Authors:  Noritoshi Kato; Tomoki Kosugi; Waichi Sato; Takuji Ishimoto; Hiroshi Kojima; Yuka Sato; Kazuma Sakamoto; Shoichi Maruyama; Yukio Yuzawa; Seiichi Matsuo; Kenji Kadomatsu
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

3.  (18)F-FDG PET/CT imaging detects therapy efficacy of anti-EMMPRIN antibody and gemcitabine in orthotopic pancreatic tumor xenografts.

Authors:  Nemil Shah; Guihua Zhai; Joseph A Knowles; Cecil R Stockard; William E Grizzle; Naomi Fineberg; Tong Zhou; Kurt R Zinn; Eben L Rosenthal; Hyunki Kim
Journal:  Mol Imaging Biol       Date:  2012-04       Impact factor: 3.488

4.  Fibroblast stimulation of blood vessel development and cancer cell invasion in a subrenal capsule xenograft model: stress-induced premature senescence does not increase effect.

Authors:  Dan Liu; Peter J Hornsby
Journal:  Neoplasia       Date:  2007-05       Impact factor: 5.715

5.  EMMPRIN/CD147 expression is associated with disease-free survival of patients with colorectal cancer.

Authors:  Shaojun Zhu; Dake Chu; Yang Zhang; Xuxia Wang; Li Gong; Xiujuan Han; Li Yao; Miao Lan; Yanhong Li; Wei Zhang
Journal:  Med Oncol       Date:  2013-02-07       Impact factor: 3.064

6.  Co-expression of CD147 and GLUT-1 indicates radiation resistance and poor prognosis in cervical squamous cell carcinoma.

Authors:  Xin-Qiong Huang; Xiang Chen; Xiao-Xue Xie; Qin Zhou; Kai Li; Shan Li; Liang-Fang Shen; Juan Su
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

7.  Expression and clinical significance of extracellular matrix metalloproteinase inducer, EMMPRIN/CD147, in human osteosarcoma.

Authors:  Qiang Lu; Gang Lv; Andre Kim; Jong-Myung Ha; Suhkman Kim
Journal:  Oncol Lett       Date:  2012-10-19       Impact factor: 2.967

8.  Prediction of prognosis in gallbladder carcinoma by CD147 and MMP-2 immunohistochemistry.

Authors:  Wei Wu; Rongbing Wang; Hui Liu; Jie Peng; Damao Huang; Bo Li; Jingde Ruan
Journal:  Med Oncol       Date:  2008-07-30       Impact factor: 3.064

9.  EMMPRIN expression is required for response to bevacizumab therapy in HNSCC xenografts.

Authors:  J Robert Newman; Emily E Helman; Seena Safavy; Wenyue Zhang; Eben L Rosenthal
Journal:  Cancer Lett       Date:  2008-11-05       Impact factor: 8.679

10.  Identification of novel tumor antigens with patient-derived immune-selected antibodies.

Authors:  Daniel Rodriguez-Pinto; Jason Sparkowski; Martin P Keough; Kathryn N Phoenix; Frank Vumbaca; David K Han; Eckart D Gundelfinger; Philip Beesley; Kevin P Claffey
Journal:  Cancer Immunol Immunother       Date:  2008-06-21       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.